, Volume 15, Issue 4, pp 1055–1062 | Cite as

Marked Age-Related Changes in Brain Iron Homeostasis in Amyloid Protein Precursor Knockout Mice

  • Abdel A. Belaidi
  • Adam P. Gunn
  • Bruce X. Wong
  • Scott Ayton
  • Ambili T. Appukuttan
  • Blaine R. Roberts
  • James A. Duce
  • Ashley I. BushEmail author
Original Article


Proteolytic cleavage of the amyloid precursor protein (APP) into the Aβ peptide has been an extensively researched mechanism for Alzheimer’s disease, but the normal function of the protein is less understood. APP functions to regulate neuronal iron content by stabilizing the surface presentation of ferroportin—the only iron exporter channel of cells. The present study aims to quantify the contribution of APP to brain and peripheral iron by examining the lifetime impact on brain and liver iron levels in APP knockout mice. Consistent with previous reports, we found that wild-type mice exhibited an age-dependent increase in iron and ferritin in the brain, while no age-dependent changes were observed in the liver. APP ablation resulted in an exaggeration of age-dependent iron accumulation in the brain and liver in mice that was assessed at 8, 12, 18, and 22 months of age. Brain ferroportin levels were decreased in APP knockout mice, consistent with a mechanistic role for APP in stabilizing this iron export protein in the brain. Iron elevation in the brain and liver of APP knockout mice correlated with decreased transferrin receptor 1 and increased ferritin protein levels. However, no age-dependent increase in brain ferritin iron saturation was observed in APP-KO mice despite similar protein expression levels potentially explaining the vulnerability of APP-KO mice to parkinsonism and traumatic brain sequelae. Our results support a crucial role of APP in regulating brain and peripheral iron, and show that APP may act to oppose brain iron elevation during aging.


Amyloid precursor protein Iron Ferritin Brain Neurodegeneration 



Support by the National Health and Medical Council of Australia (NHMRC), the Australian Research Council, and the German Research Foundation (DFG: BE 5471/1-1 to AAB) is gratefully acknowledged.

Required Author Forms

Disclosure forms provided by the authors are available with the online version of this article.

Compliance with Ethical Standards

All mouse studies were performed with the approval of the IACUC and in accordance with statutory regulations.

Conflict of Interest

BR receives research support for Agilent. AIB is a shareholder in Prana Biotechnology Ltd., Cogstate Ltd., Brighton Biotech LLC, Grunbiotics Pty Ltd., Eucalyptus Pty Ltd., and Mesoblast Ltd. He is a paid consultant for, and has a profit share interest in, Collaborative Medicinal Development Pty Ltd.

Supplementary material

13311_2018_656_MOESM1_ESM.pdf (1.2 mb)
ESM 1 (PDF 1225 kb)


  1. 1.
    Caldwell JH, Klevanski M, Saar M, Muller UC (2013) Roles of the amyloid precursor protein family in the peripheral nervous system. Mech Dev 130, 433–446.CrossRefGoogle Scholar
  2. 2.
    Needham BE, Ciccotosto GD, Cappai R (2014) Combined deletions of amyloid precursor protein and amyloid precursor-like protein 2 reveal different effects on mouse brain metal homeostasis. Metallomics 6, 598–603.CrossRefGoogle Scholar
  3. 3.
    McCarthy RC, Park YH, Kosman DJ (2014) sAPP modulates iron efflux from brain microvascular endothelial cells by stabilizing the ferrous iron exporter ferroportin. EMBO Rep 15, 809–815.CrossRefGoogle Scholar
  4. 4.
    Wong BX, Tsatsanis A, Lim LQ, Adlard PA, Bush AI, Duce JA (2014) beta-Amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin. PLoS One 9, e114174.CrossRefGoogle Scholar
  5. 5.
    Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K, Leong SL, Perez K, Johanssen T, Greenough MA, Cho HH, Galatis D, Moir RD, Masters CL, McLean C, Tanzi RE, Cappai R, Barnham KJ, Ciccotosto GD, Rogers JT, Bush AI (2010) Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer’s disease. Cell 142, 857–867.CrossRefGoogle Scholar
  6. 6.
    Maynard CJ, Cappai R, Volitakis I, Cherny RA, White AR, Beyreuther K, Masters CL, Bush AI, Li QX (2002) Overexpression of Alzheimer’s disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem 277, 44670–44676.CrossRefGoogle Scholar
  7. 7.
    Maynard CJ, Cappai R, Volitakis I, Cherny RA, Masters CL, Li QX, Bush AI (2006) Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: implications for Alzheimer beta-amyloid pathology. J Inorg Biochem 100, 952–962.CrossRefGoogle Scholar
  8. 8.
    Ayton S, Lei P, Hare DJ, Duce JA, George JL, Adlard PA, McLean C, Rogers JT, Cherny RA, Finkelstein DI, Bush AI (2015) Parkinson’s disease iron deposition caused by nitric oxide-induced loss of beta-amyloid precursor protein. J Neurosci 35, 3591–3597.CrossRefGoogle Scholar
  9. 9.
    Ayton S, Zhang M, Roberts BR, Lam LQ, Lind M, McLean C, Bush AI, Frugier T, Crack PJ, Duce JA (2014) Ceruloplasmin and beta-amyloid precursor protein confer neuroprotection in traumatic brain injury and lower neuronal iron. Free Radic Biol Med 69, 331–337.CrossRefGoogle Scholar
  10. 10.
    Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5, 863–873.CrossRefGoogle Scholar
  11. 11.
    Hare D, Ayton S, Bush A, Lei P (2013) A delicate balance: iron metabolism and diseases of the brain. Front Aging Neurosci 5, 34.CrossRefGoogle Scholar
  12. 12.
    Arosio P, Ingrassia R, Cavadini P (2009) Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta 1790, 589–599.CrossRefGoogle Scholar
  13. 13.
    Arosio P, Levi S (2010) Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage. Biochim Biophys Acta 1800, 783–792.CrossRefGoogle Scholar
  14. 14.
    Meyron-Holtz EG, Ghosh MC, Iwai K, LaVaute T, Brazzolotto X, Berger UV, Land W, Ollivierre-Wilson H, Grinberg A, Love P, Rouault TA (2004) Genetic ablations of iron regulatory proteins 1 and 2 reveal why iron regulatory protein 2 dominates iron homeostasis. EMBO J 23, 386–395.CrossRefGoogle Scholar
  15. 15.
    Belaidi AA, Bush AI (2016) Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics. J Neurochem 139 Suppl 1, 179–197.Google Scholar
  16. 16.
    Hallgren B, Sourander P (1958) The effect of age on the non-haemin iron in the human brain. J Neurochem 3, 41–51.CrossRefGoogle Scholar
  17. 17.
    Ramos P, Santos A, Pinto NR, Mendes R, Magalhaes T, Almeida A (2014) Iron levels in the human brain: a post-mortem study of anatomical region differences and age-related changes. J Trace Elem Med Biol 28, 13–17.CrossRefGoogle Scholar
  18. 18.
    Pfefferbaum A, Adalsteinsson E, Rohlfing T, Sullivan EV (2009) MRI estimates of brain iron concentration in normal aging: comparison of field-dependent (FDRI) and phase (SWI) methods. Neuroimage 47, 493–500.CrossRefGoogle Scholar
  19. 19.
    Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ (1992) Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer’s disease. J Neurosci Res 31, 327–335.CrossRefGoogle Scholar
  20. 20.
    Jack CR, Jr., Wengenack TM, Reyes DA, Garwood M, Curran GL, Borowski BJ, Lin J, Preboske GM, Holasek SS, Adriany G, Poduslo JF (2005) In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer’s transgenic mice. J Neurosci 25, 10041–10048.CrossRefGoogle Scholar
  21. 21.
    LeVine SM (1997) Iron deposits in multiple sclerosis and Alzheimer’s disease brains. Brain Res 760, 298–303.CrossRefGoogle Scholar
  22. 22.
    Ayton S, Faux NG, Bush AI, Alzheimer's Disease Neuroimaging I (2015) Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE. Nat Commun 6, 6760.CrossRefGoogle Scholar
  23. 23.
    Ayton S, Fazlollahi A, Bourgeat P, Raniga P, Ng A, Lim YY, Diouf I, Farquharson S, Fripp J, Ames D, Doecke J, Desmond P, Ordidge R, Masters CL, Rowe CC, Maruff P, Villemagne VL, Australian Imaging B, Lifestyle Research G, Salvado O, Bush AI (2017) Cerebral quantitative susceptibility mapping predicts amyloid-beta-related cognitive decline. Brain 140, 2112–2119.CrossRefGoogle Scholar
  24. 24.
    Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW, Heavens RP, Dawson GR, Boyce S, Conner MW, Stevens KA, Slunt HH, Sisoda SS, Chen HY, Van der Ploeg LH (1995) beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 81, 525–531.CrossRefGoogle Scholar
  25. 25.
    Hare DJ, Grubman A, Ryan TM, Lothian A, Liddell JR, Grimm R, Matsuda T, Doble PA, Cherny RA, Bush AI, White AR, Masters CL, Roberts BR (2013) Profiling the iron, copper and zinc content in primary neuron and astrocyte cultures by rapid online quantitative size exclusion chromatography-inductively coupled plasma-mass spectrometry. Metallomics 5, 1656–1662.CrossRefGoogle Scholar
  26. 26.
    Gozzelino R (2016) The pathophysiology of heme in the brain. Curr Alzheimer Res 13, 174–184.CrossRefGoogle Scholar
  27. 27.
    James SA, Roberts BR, Hare DJ, de Jonge MD, Birchall IE, Jenkins NL, Cherny RA, Bush AI, McColl G (2015) Direct in vivo imaging of ferrous iron dyshomeostasis in ageing Caenorhabditis elegans. Chem Sci 6, 2952–2962.CrossRefGoogle Scholar
  28. 28.
    Wang SM, Fu LJ, Duan XL, Crooks DR, Yu P, Qian ZM, Di XJ, Li J, Rouault TA, Chang YZ (2010) Role of hepcidin in murine brain iron metabolism. Cell Mol Life Sci 67, 123–133.CrossRefGoogle Scholar
  29. 29.
    Vela D (2018) Hepcidin, an emerging and important player in brain iron homeostasis. J Transl Med 16, 25.CrossRefGoogle Scholar
  30. 30.
    Zecca L, Gallorini M, Schunemann V, Trautwein AX, Gerlach M, Riederer P, Vezzoni P, Tampellini D (2001) Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem 76, 1766–1773.CrossRefGoogle Scholar
  31. 31.
    Connor JR, Menzies SL, St Martin SM, Mufson EJ (1992) A histochemical study of iron, transferrin, and ferritin in Alzheimer’s diseased brains. J Neurosci Res 31, 75–83.CrossRefGoogle Scholar
  32. 32.
    Zhu WZ, Zhong WD, Wang W, Zhan CJ, Wang CY, Qi JP, Wang JZ, Lei T (2009) Quantitative MR phase-corrected imaging to investigate increased brain iron deposition of patients with Alzheimer disease. Radiology 253, 497–504.CrossRefGoogle Scholar
  33. 33.
    Smith MA, Zhu X, Tabaton M, Liu G, McKeel DW, Jr., Cohen ML, Wang X, Siedlak SL, Dwyer BE, Hayashi T, Nakamura M, Nunomura A, Perry G (2010) Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis 19, 363–372.CrossRefGoogle Scholar
  34. 34.
    Qin Y, Zhu W, Zhan C, Zhao L, Wang J, Tian Q, Wang W (2011) Investigation on positive correlation of increased brain iron deposition with cognitive impairment in Alzheimer disease by using quantitative MR R2' mapping. J Huazhong Univ Sci Technolog Med Sci 31, 578–585.CrossRefGoogle Scholar
  35. 35.
    Ji C, Steimle BL, Bailey DK, Kosman DJ (2018) The ferroxidase hephaestin but not amyloid precursor protein is required for ferroportin-supported iron efflux in primary hippocampal neurons. Cell Mol Neurobiol 38, 941–954.CrossRefGoogle Scholar
  36. 36.
    Gunn AP, Roberts BR (2017) Analysis of trace elements and metalloproteins in fractionated human brain samples using size exclusion inductively coupled mass spectrometry. Metals in the Brain: Measurement and Imaging 124, 119–125.CrossRefGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2018

Authors and Affiliations

  1. 1.Melbourne Dementia Research Centre, The Florey Institute of Neuroscience and Mental HealthThe University of MelbourneParkvilleAustralia
  2. 2.Alzheimer’s Research UK Cambridge Drug Discovery InstituteUniversity of CambridgeCambridgeUK

Personalised recommendations